Morepen Laboratories Limited has informed the Exchange that Board of Directors at its meeting held on May 12, 2025, recommended Final Dividend of Rs. 0.20 per equity share.

Corporate Actions View source PDF Explain this filing

MOREPENLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.8%Reaction day

₹60.52

prior close

₹59.26

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.6%-2.4% vs market

Pharmaceuticals peers, median of 149sector+0.9%-1.7% vs sector

On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.5

10m

-0.5

15m

-0.2

30m

+0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.8+1.6-2.4+0.9-1.7

Next day

-0.4+3.3-3.7+2.0-2.4

+0.6+4.3-3.7+2.4-1.8

+0.1+5.1-5.0+3.2-3.1

+5.7+6.4-0.6+3.7+2.0

+3.9+5.2-1.3+3.5+0.5

+11.9+5.9+5.9+3.6+8.3

15d

+6.4+8.0-1.6+3.9+2.5

+7.2+9.8-2.6+5.9+1.3

+3.9+11.8-7.9+7.4-3.5

-22.0+7.2-29.2+3.2-25.2

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 149Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Directors, at its meeting on May 12, 2025, recommended a final dividend of Rs. 0.20 per equity share (face value Rs. 2) for FY25, subject to shareholder approval. The company reported consolidated FY25 total income of Rs. 1,82,993.95 lakhs (up ~7.4% YoY) and net profit of Rs. 11,802.04 lakhs (up ~22.7% YoY), with EPS of Rs. 2.20 vs Rs. 1.88. Standalone performance was weaker, with net profit declining ~8.4% YoY to Rs. 10,157.52 lakhs and EPS at Rs. 1.90 vs Rs. 2.17. The Board approved an addendum to the Business Transfer Agreement with subsidiary Morepen Medipath Limited, revising the appointed date for the medical devices hive-off from February 1, 2025 to April 1, 2025. A wholly owned subsidiary will be incorporated in Dubai, UAE, to expand B2B and B2C medical device business. Dr. Morepen Limited's shareholding was diluted from 100% to 80% via warrant conversion, and Quick Med Private Limited was acquired as a step-down subsidiary with 64% effective holding.

Likely market impact

The final dividend of Rs. 0.20/share is modest (10% on face value) and needs shareholder approval at the upcoming AGM. The mixed financial picture — strong consolidated growth driven by subsidiaries but a decline in standalone profits — along with ongoing corporate restructuring (medical device hive-off, share dilution, new acquisitions) suggests strategic reshaping of the business that investors should monitor for execution and future margin impact.